Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd. (referred to as "Shangyao Xinyi"), has received the drug clinical trial approval notice for WST03 preparations (capsules) from the National Medical Products Administration, and will soon initiate Phase I clinical trials in China. WST03 is a vaginal microecological preparation for the treatment of bacterial vaginosis (BV) with demonstrated effectiveness in preclinical studies in both treatment and preventing relapse.
According to the announcement of Shanghai Pharmaceutical (601607.SH), its wholly-owned subsidiary, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., Ltd. ("Shangyao Xinyi"), has received the drug clinical trial approval notice for WST03 preparations (capsules) by the National Medical Products Administration, and is scheduled to conduct Phase I clinical trials in China soon. WST03 is a vaginal probiotic preparation developed for the treatment of bacterial vaginosis (BV), with preclinical studies indicating that it is effective in treating BV and preventing its recurrence.